181 results about "Phosphatidic acid" patented technology

The present invention relates to novel compositions and therapeutic methods for the treatment of pain, in particular neuropathic, ischemic, muscle, arthritic or multiple sclerosis pain. The compositions include a combination of an alpha2-adrenergic agonist or a nitric oxide donor combined with a phosphodiesterase (PDE) or a phosphatidic acid (PA) inhibitor, which have been found to act together synergistically to provide effective treatment for pain, especially when administered topically.

The present invention relates to a pharmaceutical composition for treatment and/or prevention for urinary diseases comprising a lysophosphatidic acid (LPA) receptor regulator.

As LPA receptor regulators act on urethra and prostate, compounds acting on this receptor are useful in treating urinary diseases (urinary incontinence, dysuria, etc.). For example, an LPA receptor agonist useful for treatment of urinary incontinence, while an LPA receptor antagonist is useful for treatment of dysuria, ischuria, pollakiuria, nocturia, urodynia and benign prostatic hyperplasia.

Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of phosphatidic acid for administration is phosphatidic acid-enriched lecithin. Creatine is co-administered orally to increase the muscle-building and strength effect. Other suggested additives include nutritional and herbal supplements, micronutrients and hormones.

The invention relates to a method for preparing phosphatidyserine. The method for preparing phosphatidyserine comprises the following steps of mixing phosphatidylcholine or natural phospholipid containing phosphatidylcholine with tween-80, L-serine, calcium chloride, buffer solution and phospholipase D, and stirring and reacting the above materials at 35-45 DEG C for 8-10h; separating out the crude products from reaction and floating, carrying out centrifugal separation on the aqueous phase and crude products, washing the crude products subjected to separation and carrying out centrifugal filtration; adding the crude products subjected to centrifugal filtration into absolute ethyl alcohol for immersing, stirring, and carrying out centrifugal filtration; and carrying out vacuum drying on the products subjected to centrifugal filtration to obtain the phosphatidyserine. The invention aims to provide a new method for preparing phosphatidyserine to solve the problems that in the prior art, the byproduct of phosphatidic acid is large in amount, the conversion rate is unsatisfactory and the product cost is high.

In the present invention, cDNA microarrays to investigate pituitary gene expression in two chicken lines that were selected for low and high body fat (Lean and Fat). Differentially expressed genes between lines are potential candidates as genetic markers for high and low potential for body fat accumulation. The lysophosphatidic acid (LPA) receptor-1 (LPAR1) was identified as a potential marker, being differentially expressed between the lean and fat lines at the early ages. The invention provides SNPs that can introduce a GATA site in the promoter of LPAR1 which can upregulate its expression in the lean chickens, and increased LPA signaling and which can inhibit preadipocyte differentiation. Conversely, SNPs are provided that cause loss of the GATA binding site and cause decreased levels of LPAR1 expression and attenuated inhibition of adipocyte maturation in fat chickens.

Recombinant microbial cells are disclosed herein that produce an oil comprising at least 28 percent eicosapentaenoic acid (EPA) measured as a weight percent of dry cell weight. These cells may comprise a polynucleotide sequence encoding an active acyl-CoA:lysophosphatidylcholine acyltransferase (LPCAT) comprising at least one amino acid mutation in a membrane-bound O-acyltransferase motif. In addition, the cells may comprise a down-regulation of an endogenous polynucleotide sequence encoding Sou2 sorbitol utilization protein, and/or one or more polynucleotides encoding phospholipid:diacylglycerol acyltransferase (PDAT), delta-12 desaturase, a dihomo-gamma-linolenic acid (DGLA) synthase multizyme, delta-8 desaturase, malonyl-CoA synthetase (MCS), or acyl-CoA:lysophosphatidic acid acyltransferase (LPAAT). Also disclosed are methods of using the recombinant microbial cells to produce oil containing omega-3 polyunsaturated fatty acids such as EPA.

The invention discloses a method for preparing phosphatidylserine. According to the method, phospholipid and L-serine are subjected to phospholipid translating acylation reaction under the action of phospholipase D to generate the phosphatidylserine, wherein the phospholipid translating acylation reaction is carried out in a homogeneous medium system and the yield of the phosphatidylserine reaches 80-98 percent. The method disclosed by the invention has the advantages that due to the adoption of a green reaction medium, a reaction system is a homogeneous medium system. No phosphatidic acid as a byproduct is generated, high catalytic efficiency of enzyme and favorable quality of products are obtained and the process is safe and environment-friendly.

The invention relates to oligoarginine modified phospholipid, nanoparticles assembled by the oligoarginine modified phospholipid, a preparation method of the oligoarginine modified phospholipid and an application of the nanoparticles. After oligoarginine peptide chains are activated by DCC (dicyclohexylcarbodiimide)/NHS (N-hydroxysuccinimide), the oligoarginine peptide chains react with phosphatidyl ethanolamine, purification is performed, and oligoarginine modified phosphatidyl ethanolamine is obtained; or the oligoarginine peptide chains react with DCC/NHS activated phosphatidic acid, and oligoarginine modified phosphatidic acid is obtained through purification; or the oligoarginine peptide chains react with nitrophenyl chloroformate activated phosphatidylcholine, and oligoarginine modified phosphatidylcholine is obtained through purification. The nanoparticles assembled by the oligoarginine modified phospholipid is used for supporting genes, small-interfering RNA, polypeptides or proteinic drugs, antibodies and chemical drugs, and the formed aqueous dispersion of the drug-carrying nanoparticles is used for delivering drugs for in-vitro cells or in-vivo local intravenous injection. The nanoparticles are effectively promoted to enter the cells, and the intracellular drug delivery efficiency is improved.

Disclosed is a lipid preparation comprising a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The disclosed preparations possess an improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes, for example ADHD.

PCT No. PCT/IL97/00147 Sec. 371 Date Feb. 24, 1999 Sec. 102(e) Date Feb. 24, 1999 PCT Filed May 6, 1997 PCT Pub. No. WO97/41874 PCT Pub. Date Nov. 13, 1997The invention is to a method for the treatment of withdrawal symptoms selected from the group consisting of nausea, sweating, shaking, substance craving and hot flushes.

The invention relates to the technical field of drink processing, in particular to a passion fruit drink and a preparation method thereof. The passion fruit drink is mainly prepared from passion fruits, pitaya, wax apples, endive, Jerusalem artichoke, purple lotus fruits, dark green tea, twisted-flower rush herb, phosphatidic acid, mannan, chitosan, lactobacillus fermenti, lactobacillus acidophilus, bacillus licheniformis, bifidobacterium, saccharomycetes, lactosucrose, isomaltooligosaccharide, stachyose, complex enzyme and other raw materials through raw material treatment, enzymolysis, enzyme deactivation, blending, sterilization and other steps. The raw material formula of the drink is the most scientific and reasonable, the drink has uniform color, has no precipitates, has a fragrant and strong fruit flavor, tastes mellow, refreshing, sour, sweet and delicious, has a long shelf life, has effectively increased soluble solid content, has high nutritional value, can effectively promote intestinal tract movement, has the effects of clearing heat, removing toxins, producing saliva, slaking thirst, clearing intestines, maintaining beauty and keeping young and is a functional healthcare drink capable of regulating intestinal florae and invigorating intestines and stomach, and the preparation process is simple and easy to operate.

The invention belongs to the technical field of medicine, and particularly relates to a carboxylic acid derivative as a lysophosphatidic acid receptor antagonist as shown in a general formula (I) and a pharmaceutically acceptable salt thereof or an stereomer thereof, wherein A, B, C, D, E, R1, R3, R4, R5, RA, RB, RC, m and p are as defined in the specification. The invention also relates to preparation methods of the compounds, a drug composition or a drug preparation which contains the compounds and an important application of the compounds in preparing a drug for treating and/or preventing LPA-dependence or LPA-mediation diseases.

The invention discloses a method for preparing an omega-3 fatty acid-rich phospholipid from algal oil. The method comprises 1) acquiring algal oil, 2) separating algal oil phospholipid through addingfood grade acetone into the algae oil, carrying out full mixing for 45-60min, carrying out centrifugation at 4000-5000 rpm/min for 15-20 min to obtain precipitates which are crude algal oil phospholipid and repeating the above processes, 3) purifying phosphatidylcholine through eluting a chromatographic column through ethanol for a silica gel chromatographic column to separate and remove phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and phosphatidic acid and then separating and collecting phosphatidylcholine through elution of the chromatographic column with ethanol, and 4) synthesizing omega-3 fatty acid-rich phospholipid through mixing the extracted crude algal oil phospholipid or phosphatidylcholine and ethanol, adding lipase and an appropriate amount of water intothe mixture and preparing the omega-3 fatty acid-rich phospholipid through the lipase alcoholysis reaction. When the phosphatidylcholine is used as a synthesizing raw material, the total content of the omega-3 fatty acid after the enzyme catalytic reaction can reach to 70% or more.

Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening(HTS) for identification of potential inhibitors of lysoPLD activity.

The invention relates to the medical field, and discloses a culture medium for neural stem cell proliferation and capable of inducing neural stem cell to differentiate to dopaminergic neuron and an application and proliferation inducing method. The proliferation culture medium is a culture medium using DMEM/F12 as the base. The culture medium comprises insulin human, progesterone, hydrocortisone, dexamethasone, estradiol, transferrin, EGF, FGF, CTGF, B-NGF, VEGF, a soybean pancreatin inhibitor, L-glutathione, oleic acid, Tween 80, phosphatidic acid, sodium selenite, panax notoginseng saponins, resveratrol, lithium chloride, cholesterol, WNT3a, and glutamine. A novel neural stem cell culture medium is formed by using a plurality of suitable components with low cost and extensive sources, the proliferation speed of the neural stem cells is remarkably improved, and other induced differentiation components are added on the basis of the neural stem cell, so the neural stem cell is induced to be differentiated to the dopaminergic neuron, and the differentiation proportion is remarkably improved.

The invention discloses low-temperature-resistant phospholipase D derived from Antarctic bacteria and a preparation method and application thereof. The amino acid sequence of the low-temperature-resistant phospholipase D is shown as SEQ ID NO: 3; and the gene sequence of the low-temperature-resistant phospholipase D is shown as SEQ ID NO: 2. An escherichia coli recombinant expression strain of the low-temperature-resistant phospholipase D is obtained, by means of the strain, a large amount of soluble expression of recombinant protein can be achieved, and later purification and protein obtaining are easy. The expression product has good low-temperature storage stability and good enzyme activity, and meanwhile has certain tolerance to organic solvents and surfactants. The obtained phospholipase D can be suitable for phospholipid modification, phosphatidic acid and various natural rare phospholipid and non-natural phospholipid compounds are produced, and the phospholipase D is applied to the fields of biology, food, medicine, cosmetics, agriculture, industry and the like.

The invention provides a preparation method of a multifunctional electrospinning scaffold for bone regeneration. The method belongs to the field of tissue engineering and regenerative medicine, and comprises the following specific steps: 1, preparing lysophosphatidic acid nanoparticles and deferoxamine nanoparticles; 2, preparing a medical polymer mixed solution and dividing the medical polymer mixed solution into two equal parts; 3, preparing a coaxial electrospinning shell layer solution from the lysophosphatidic acid nanoparticles, zinc oxide nanoparticles and the medical polymer mixed solution; 4, preparing a coaxial electrospinning core layer solution from the deferoxamine nanoparticles and another medical polymer mixed solution; 5, preparing the electrospinning scaffold with a core-shell structure; and 6, performing vacuum drying until a solvent is removed, thereby finally obtaining the product. According to the prepared multifunctional electrospinning scaffold for bone regeneration, the lysophosphatidic acid nanoparticles and the zinc oxide nanoparticles are arranged on the shell layer, the deferoxamine nanoparticles are arranged on the core layer, and the electrospinning scaffold has the functions of resisting bacteria, promoting osteogenesis, promoting revascularization and the like at the same time and can be used for repairing bone tissues in a complex microenvironment.